glp-1 companies list of approved and pending medications GLP-1 Therapies Evolve with Multi-Hormone – GLP-1 drug boom set to

Executive Summary Written by Jonathan Wright, British Clinical Pharmacist Last reviewed: February 2026 Glucagon-like peptide-1 (GLP-1) receptor agonists including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have transformed the treatment of obesity and type 2 diabetes

Foundayo appears to be the latest advancement toward convenience and flexibility in the GLP-1 agonist space

They also secrete toxins, including hemolysins and enterotoxins, which damage host cells, facilitate tissue destruction, and trigger further inflammatory responses

During early clinical trials, diabetic patients began to report substantial weight loss as an unexpected but positive side effect of taking semaglutide to manage their blood sugar levels